17 januari, 2025 Regulatoriskt AcuCort's Chairman subscribes for an additional approximately SEK 200,000 in the ongoing rights issue
14 januari, 2025 Regulatoriskt AcuCort’s CEO subscribes for an additional SEK 1 million in the ongoing rights issue, bringing total commitment to approximately SEK 2 million
11 mars, 2024 Regulatoriskt Insider trading in subscription option TO1 - CEO Jonas Jönmark increases his stake in AcuCort AB
30 november, 2023 Regulatoriskt AcuCort publishes the Interim Report for the third quarter 2023 (in Swedish)
31 augusti, 2023 Regulatoriskt AcuCort signs partnership agreement for the four major Nordic countries with Unimedic Pharma
28 april, 2023 Regulatoriskt AcuCort publishes the Interim Report for the first quarter 2023 (in Swedish)
20 februari, 2023 Regulatoriskt The FDA is requesting additional information prior to AcuCort's registration application in the United States
24 januari, 2023 Regulatoriskt AcuCort receives market approval from the Finnish Medicines Agency for the drug Zeqmelit®
23 november, 2022 Regulatoriskt AcuCort signs its first commercial agreement for the company’s drug Zeqmelit™
11 november, 2022 Regulatoriskt AcuCort publishes the Interim Report for the third quarter 2022 (in Swedish)
19 oktober, 2022 Regulatoriskt AcuCort receives a granted patent in Canada for the company's drug Zeqmelit™
27 september, 2022 Regulatoriskt AcuCort receives marketing authorization for the drug Zeqmelit by the Norwegian Medicines Agency
16 augusti, 2022 Regulatoriskt AcuCort receives marketing authorization for the drug Zeqmelit by the Danish Medicines Agency
12 augusti, 2022 Regulatoriskt AcuCort publishes the Interim Report for the second quarter 2022 (in Swedish)
8 juni, 2022 Regulatoriskt AcuCort’s application for ethical review for a questionnaire study on allergy treatment is approved
28 april, 2022 Regulatoriskt AcuCort publishes the Interim Report for the first quarter 2022 (in Swedish)
26 april, 2022 Regulatoriskt AcuCort applies for ethical review for a questionnaire study on allergy treatment
1 mars, 2022 Regulatoriskt AcuCort is exempted from the application fee by the U.S. Food and Drug Administration
22 februari, 2022 Regulatoriskt AcuCort enters agreement with the pharmaceutical manufacturer Adhex Pharma regarding commercial and large-scale production of ISICORT®
17 februari, 2022 Regulatoriskt AcuCort announces that the company signs an agreement with consulting company in pharmacovigilance before the upcoming commercialization of ISICORT®
15 november, 2021 Regulatoriskt AcuCort announces that the registration process in the Nordic market is underway for the company’s drug ISICORT®
11 augusti, 2021 Regulatoriskt AcuCort announces that the Board of Directors and the CEO have subscribed for options to purchase shares in the company
26 april, 2021 Regulatoriskt AcuCort progresses into a new phase and strengthens the commercialization team
7 oktober, 2020 Regulatoriskt AcuCort receives market approval from the Swedish Medical Products Agency for the drug ISICORT®
28 maj, 2020 Regulatoriskt AcuCort comments on the status update regarding the second US patent application
17 mars, 2020 Regulatoriskt AcuCort AB: Correction, missing MAR label in the press release on March 16, 2020
13 februari, 2020 Regulatoriskt AcuCort confirms response from the Swedish MPA regarding ISICORT® market application
8 november, 2019 Regulatoriskt AcuCort gives an update on the continued work concerning the bioequivalence study for US registration
16 oktober, 2019 Regulatoriskt AcuCort reports that bioequivalence was not achieved in the second study for US registration
23 januari, 2019 Regulatoriskt AcuCort obtains regulatory approval to start bioequivalence study for the US
4 oktober, 2018 Regulatoriskt AcuCort obtains regulatory approval to start bioequivalence study for the EU
7 september, 2018 Regulatoriskt AcuCort’s allergy medicine Dexa ODF has been manufactured and released according to Good Manufacturing Practice, GMP
21 juni, 2018 Regulatoriskt AcuCort signs agreement with the CRO Quinta-Analytica concerning the performance of bioequivalence studies
12 juni, 2018 Regulatoriskt AcuCort’s allergy treatment Dexa ODF is ready to be manufactured according to GMP (Good Manufacturing Practice) for clinical use
24 april, 2018 Regulatoriskt Correction and clarification concerning the expiry dates of AcuCort’s patents
16 april, 2018 Regulatoriskt AcuCort’s patent is granted with 1,349 days extended patent protection in the US